• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by SWK Holdings Corporation (Amendment)

    2/13/24 7:18:02 PM ET
    $SWKH
    Diversified Financial Services
    Finance
    Get the next $SWKH alert in real time by email
    SC 13G/A 1 ccllc_swkh_13g021424.htm SCHEDULE 13G/A

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO §240.13d-2

    (Amendment No.2) 1


    SWK HOLDINGS CORPORATION

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    78501P203

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☑   Rule 13d-1(b)

    ☐   Rule 13d-1(c)

    ☐   Rule 13d-1(d)

    1   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

         The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
    CUSIP No.78501P203 Page 2 of 7 Pages
    1

    NAMES OF REPORTING PERSONS

    J. Carlo Cannell

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    USA

    NUMBER OF SHARES

    BENEFICIALLY OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    823,652

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    823,652

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    823,652

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐

    (see instructions)

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

    6.59%

    12

    TYPE OF REPORTING PERSON

    IN, HC

     
    CUSIP No.78501P203 Page 3 of 7 Pages
    1

    NAMES OF REPORTING PERSONS

    I.R.S. Identification Nos. of Above Persons (Entities Only)

    Cannell Capital LLC

    94-3366999

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Wyoming, USA

    NUMBER OF SHARES

    BENEFICIALLY OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    823,652

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    823,652

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    823,652

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐

    (see instructions)

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

    6.59%

    12

    TYPE OF REPORTING PERSON

    IA

     
    CUSIP No.78501P203 Page 4 of 7 Pages
    Item 1.

    a)

    Name of Issuer

    SWK Holdings Corporation

    b)

    Address of issuer's principal executive offices:

    5956 Sherry Lane, Suite 650

    Dallas, TX 75225

    Item 2.

    a)

    Name of person filing:

    Cannell Capital LLC

    b)

    Address or principal business office or, if none, residence:

    245 Meriwether Circle

    Alta, WY 83414

    c)

    Citizenship:

    Wyoming, USA

    d)

    Title of class of securities:

    Common Stock

    e)

    CUSIP No.:

    78501P203

    Item 3.
    If this statement is filed pursuant to §240.13d-1(b) or §240.13d-2(b) or (c), check whether the person filing is a:

    (a)

    ☐

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

    (b)

    ☐

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c)

    ☐

    Insurance company as defined in section 3(a)(19) of the Act(15 U.S.C. 78c).

    (d)

    ☐

    An Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

    (e)

    ☑

    An investment adviser in accordance with Section §240.13d-1(b)(1)(ii)(E).

    (f)

    ☐

    An Employee benefit plan or endowment fund in accordance with Section §240.13d-1(b)(1)(ii)(F).

    (g)

    ☐

    A Parent holding company or control person in accordance with Section §240.13d-1(b)(1)(ii)(G).

    (h)

    ☐

    A Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

    (i)

    ☐

    A Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).

    (j)

    ☐

    A non-U.S. institution in accordance with Section §240.13d-1(b)(1)(ii)(J).

    (k)

    ☐

    Group, in accordance with Section §240.13d-1(b)(1)(ii)(J).

     
    CUSIP No.78501P203 Page 5 of 7 Pages
    Item 4. Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a)

    Amount beneficially owned: 823,652.

    (b)

    Percent of class: 6.59%.

    (c)

    Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote 0.
    (ii) Shared power to vote or to direct the vote 823,652.
    (iii) Sole power to dispose or to direct the disposition of 0.
    (iv) Shared power to dispose or to direct the disposition of 823,652. Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

    Item 5. Ownership of 5 Percent or Less of a Class.
    Not Applicable.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
    Not Applicable.

    Item 8. Identification and Classification of Members of the Group.
    Not Applicable.

    Item 9. Notice of Dissolution of Group.
    Not Applicable.

    Item 10. Certifications.
    Not Applicable.

     
    CUSIP No.78501P203 Page 6 of 7 Pages

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    02/14/2024                            

    Date       

    By:  /s/ J. Carlo Cannell                 

    Name:  J. Carlo Cannell

    Cannell Capital LLC

    By:  /s/ J. Carlo Cannell                 

    Name:  J. Carlo Cannell

    Title:  Managing Member

     
    CUSIP No.78501P203 Page 7 of 7 Pages

    Exhibit A

    Agreement Regarding the Joint Filing of Schedule 13G

    The undersigned hereby agree as follows:
    1) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf each of them;
    2) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

    By:  /s/ J. Carlo Cannell                 

    Name:  J. Carlo Cannell

    Cannell Capital LLC

    By:  /s/ J. Carlo Cannell                 

    Name:  J. Carlo Cannell

    Title:  Managing Member

    Get the next $SWKH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SWKH

    DatePrice TargetRatingAnalyst
    12/28/2022$26.00Buy
    Lake Street
    4/18/2022$26.00Buy
    Lake Street
    More analyst ratings

    $SWKH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ImpediMed Secures $15m Growth Capital Funding

      New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Funds raised will provide ImpediMed with funding flexibility and will be used to support growth and commercialization activities. Armentum Partners acted as the Company's exclusiv

      2/7/25 11:00:00 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • SWK Holdings Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / January 6, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update for material events occurring since September 30, 2024.OriginationsIn November, SWK advanced $5.0M to existing borrower Journey Medical to help fund the company's launch of EmrosiTM.In November, as part of a broader amendment SWK advanced $0.6M to existing borrower Biotricity. On amendment closing, SWK received 600,000 warrants to purchase Biotricity stock at $0.50 per share.In December, SWK closed an $8.0M senior secured term loan with Triple

      1/6/25 7:35:00 AM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    SEC Filings

    See more
    • SWK Holdings Corporation filed SEC Form 8-K: Other Events

      8-K - SWK Holdings Corp (0001089907) (Filer)

      5/19/25 8:47:29 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SWK Holdings Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - SWK Holdings Corp (0001089907) (Filer)

      5/15/25 4:23:24 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SWK Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SWK Holdings Corp (0001089907) (Filer)

      5/15/25 4:22:48 PM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Leadership Updates

    Live Leadership Updates

    See more
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • SWK Holdings Appoints Chief Financial Officer

      Company Also Promotes Controller DALLAS, TX / ACCESSWIRE / July 8, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, is pleased to announce the appointment of Adam C. Rice, CPA, as Chief Financial Officer (CFO) of the company and the promotion of Courtney Baker, CPA, to Controller.With over 18 years of senior-level finance and accounting leadership experience, Rice has led financial operations management, corporate financial planning and analysis, strategic planning and financial statement reporting. He was previously CFO of Park Cities Asset Management, an SEC

      7/8/24 5:00:00 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Stanley Black & Decker Appoints Chris Nelson Chief Operating Officer and Executive Vice President and President of Tools & Outdoor

      NEW BRITAIN, Conn., May 2, 2023 /PRNewswire/ -- Stanley Black & Decker (NYSE:SWK) today announced the appointment of Chris Nelson as Chief Operating Officer of the company, and Executive Vice President and President of Tools & Outdoor, effective June 14, 2023. Nelson joins Stanley Black & Decker from Carrier Corporation and brings more than 25 years of leadership experience in general management, product development and innovation, and growth transformation. Nelson will report to Donald Allan Jr., President and CEO of Stanley Black & Decker. He will assume the role of President, Tools & Outdoor, from current Acting Co-Presidents Robert Raff and John Wyatt. Raff will continue to serve as Chie

      5/2/23 4:36:00 PM ET
      $SWK
      $SWKH
      Industrial Machinery/Components
      Consumer Discretionary
      Diversified Financial Services
      Finance

    $SWKH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT Staggs Joe David Jr exercised 33,750 shares at a strike of $11.22 and covered exercise/tax liability with 25,857 shares, increasing direct ownership by 7% to 123,766 units (SEC Form 4)

      4 - SWK Holdings Corp (0001089907) (Issuer)

      4/17/25 4:34:14 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • PRESIDENT Staggs Joe David Jr was granted 36,700 shares, increasing direct ownership by 46% to 115,873 units (SEC Form 4)

      4 - SWK Holdings Corp (0001089907) (Issuer)

      2/4/25 4:14:55 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Chief Financial Officer Rice Adam was granted 9,175 shares, increasing direct ownership by 151% to 15,247 units (SEC Form 4)

      4 - SWK Holdings Corp (0001089907) (Issuer)

      2/4/25 4:14:24 PM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Financials

    Live finance-specific insights

    See more
    • SWK Holdings Corporation Announces Financial Results for Third Quarter 2024

      Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CSTCorporate HighlightsThird quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023.Third quarter 2024 finance receivables segment adjusted non-GAAP net income was $5.0 million, compared with adjusted non-GAAP net income of $5.8 million for the third quarter 2023.As of September 30, 2024, net finance receivables were $255.9 million, a 14.4% increase from September 30, 2023.The third quarter 2024 effective yield was 14.6%, a 60 basis points increase from third quarter 2023.As of September 30, 2024, GAAP book value per share was $22.94, a 3.7% increase from $2

      11/14/24 4:15:00 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SWK Holdings Provides Portfolio Update

      Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results

      10/17/24 4:15:00 PM ET
      $BTCY
      $DERM
      $ELUT
      $ETON
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

      7/17/24 4:15:00 PM ET
      $BIOL
      $BTCY
      $DERM
      $ELUT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)

    $SWKH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SWK Holdings Corporation

      SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

      11/14/24 11:49:47 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Amendment: SEC Form SC 13D/A filed by SWK Holdings Corporation

      SC 13D/A - SWK Holdings Corp (0001089907) (Subject)

      10/25/24 4:05:56 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SEC Form SC 13G/A filed by SWK Holdings Corporation (Amendment)

      SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

      2/14/24 2:14:12 PM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street resumed coverage on SWK Holdings with a new price target

      Lake Street resumed coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

      12/28/22 9:18:49 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Lake Street initiated coverage on SWK Holdings with a new price target

      Lake Street initiated coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

      4/18/22 8:44:23 AM ET
      $SWKH
      Diversified Financial Services
      Finance